Infinity Laboratories Partners with Imperial Capital Group
Founded in 1991, Infinity operates from a 25,000 square foot, state-of-the-art facility that provides critical testing services in the areas of chemical and microbiological sciences for FDA regulated manufacturers throughout North America.
“Imperial’s investment will offer far reaching resources to Infinity,” said Daniel Henderson, President and Chief Executive Officer of the Company. “It will enable the business to initiate significant capital projects across all of the Company’s business and laboratory units, furthering its mission to provide best-in-class analytical and microbiological testing, while remaining at the forefront of regulatory compliance and customer service.”
Christopher Harris, Principal at Imperial, commented, “We are pleased to partner with Daniel Henderson and are eager to continue building on the strong growth, continuous quality improvement, and dedication to customer service that have been the hallmarks of his leadership.”
“This is an exciting time to be at Infinity,” continued Mr. Henderson, “we plan to invest across all aspects of the Company in the coming months, but above all, we are excited to further invest in our people, the most important asset in our business.”
About Infinity Laboratories
Infinity Laboratories was founded in 1991 on the bedrock principles of excellence, integrity, and quality. Today, the Company is a national chemical and microbiological testing laboratory servicing the medical device and pharmaceutical industries. For more information about Infinity Laboratories, please visit infinitylaboratories.com.
About Imperial Capital Group
Imperial Capital Group is a Toronto-based private equity fund manager that focuses on buy-out opportunities in the U.S. and Canadian middle market. Currently drawing from its sixth fund with commitments of $500 million, Imperial invests in targeted niches within the healthcare, business, and consumer services industries. For more information about Imperial, please visit imperialcap.com.
Imperial Capital Group
Expanded testing capabilities with developed method for Hydroxychloroquine (HCQ). Effective April 16, 2020 - Infinity Laboratories has added a validated method for Hydroxychloroquine and is now receiving final product samples for potency testing. Hydroxychloroquine...
CASTLE ROCK, CO - April 21, 2020 - Today Infinity Laboratories (infinitylaboratories.com) proudly announced the launch of Mycoplasma testing. Infinity Laboratories is a powerful network of state-of the - art testing facilities that are FDA Registered, ISO 17025...
Infinity Laboratories expands testing capabilities with developed method for Hydroxychloroquine (HCQ)
CASTLE ROCK, CO - April 16, 2020 - Today Infinity Laboratories (infinitylaboratories.com) added a validated method for Hydroxychloroquine to its expanding catalog of capabilities and is now receiving final product samples for potency testing. Hydroxychloroquine (HCQ)...